BS EN ISO 21676:2021
Water quality. Determination of the dissolved fraction of selected active pharmaceutical ingredients, transformation products and other organic substances in water and treated waste water. Method using high performance liquid chromatography and mass spectrometric detection (HPLC-MS/MS or -HRMS) after direct injection
Standard number: | BS EN ISO 21676:2021 |
Pages: | 44 |
Released: | 2021-08-11 |
ISBN: | 978 0 539 16731 3 |
Status: | Standard |
BS EN ISO 21676:2021 - Water Quality Standard
Standard Number: BS EN ISO 21676:2021
Pages: 44
Released: 2021-08-11
ISBN: 978 0 539 16731 3
Status: Standard
Overview
The BS EN ISO 21676:2021 standard is an essential document for professionals in the field of water quality analysis. This comprehensive standard provides a detailed methodology for the determination of the dissolved fraction of selected active pharmaceutical ingredients, transformation products, and other organic substances in water and treated wastewater. Utilizing advanced techniques such as high-performance liquid chromatography (HPLC) and mass spectrometric detection (MS/MS or HRMS) after direct injection, this standard ensures precise and reliable results.
Key Features
- Comprehensive Methodology: The standard outlines a robust method using HPLC-MS/MS or HRMS for the accurate detection of various organic substances in water.
- Wide Applicability: Suitable for analyzing both water and treated wastewater, making it versatile for different water quality monitoring needs.
- High Precision: The use of high-performance liquid chromatography and mass spectrometric detection ensures high precision and reliability in the results.
- Detailed Guidance: Provides step-by-step instructions and guidelines to ensure consistent and reproducible results.
Why Choose BS EN ISO 21676:2021?
Ensuring the quality of water is crucial for public health and environmental protection. The BS EN ISO 21676:2021 standard is designed to help laboratories and water quality professionals achieve accurate and reliable measurements of dissolved pharmaceutical ingredients and other organic substances. By following this standard, you can:
- Enhance Accuracy: The detailed methodology minimizes errors and enhances the accuracy of your water quality assessments.
- Ensure Compliance: Adhering to this internationally recognized standard helps ensure compliance with regulatory requirements and industry best practices.
- Improve Efficiency: The clear guidelines and step-by-step instructions streamline the analytical process, saving time and resources.
- Support Environmental Protection: Accurate detection of contaminants supports efforts to protect water resources and the environment.
Technical Details
The BS EN ISO 21676:2021 standard spans 44 pages and was released on August 11, 2021. It is identified by the ISBN number 978 0 539 16731 3. This standard is a valuable resource for laboratories, environmental agencies, and water quality professionals who require precise and reliable methods for analyzing water and treated wastewater.
Applications
This standard is applicable in various settings, including:
- Environmental Monitoring: Used by environmental agencies to monitor and assess the quality of water bodies.
- Water Treatment Plants: Essential for ensuring the effectiveness of water treatment processes and the safety of treated wastewater.
- Pharmaceutical Industry: Helps in monitoring the presence of pharmaceutical residues in water, ensuring compliance with environmental regulations.
- Research Laboratories: Provides a reliable method for academic and industrial research on water quality and contamination.
Conclusion
The BS EN ISO 21676:2021 standard is an indispensable tool for anyone involved in water quality analysis. Its comprehensive methodology, high precision, and wide applicability make it a valuable resource for ensuring the safety and quality of water and treated wastewater. By adhering to this standard, you can achieve accurate, reliable, and reproducible results, supporting efforts to protect public health and the environment.
BS EN ISO 21676:2021
This standard BS EN ISO 21676:2021 Water quality. Determination of the dissolved fraction of selected active pharmaceutical ingredients, transformation products and other organic substances in water and treated waste water. Method using high performance liquid chromatography and mass spectrometric detection (HPLC-MS/MS or -HRMS) after direct injection is classified in these ICS categories:
- 13.060.50 Examination of water for chemical substances
This document specifies a method for the determination of the dissolved fraction of selected active pharmaceutical ingredients and transformation products, as well as other organic substances (see Table 1) in drinking water, ground water, surface water and treated waste water.
The lower application range of this method can vary depending on the sensitivity of the equipment used and the matrix of the sample. For most compounds to which this document applies, the range is ≥ 0,025 µg/l for drinking water, ground water and surface water, and ≥ 0,050 µg/l for treated waste water.
The method can be used to determine further organic substances or in other types of water (e.g. process water) provided that accuracy has been tested and verified for each case, and that storage conditions of both samples and reference solutions have been validated. Table 1 shows the substances for which a determination was tested in accordance with the method. Table E.1 provides examples of the determination of other organic substances.
Table 1
Substances for which a determination was tested in accordance with this method
Common name Chemical name (IUPACa ) | Molecular formula | Molar mass | CAS-RNb |
---|---|---|---|
g/mol | |||
4-Acetylaminoantipyrine N-(2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl)acetamide | C13H15N3O2 | 245,28 | 83-15-8 |
N4-Acetyl sulfamethoxazole N-{4-[(5-Methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl}-acetamide | C12H13N3O4S | 295,32 | 21312-10-7 |
Diatrizoic acid (amidotricoic acid) 3,5-Bis(acetamido)-2,4,6-triiodobenzoic acid | C11H9I3N2O4 | 613,91 | 117-96-4 |
Atenolol (RS)-2-[4-[2-Hydroxy-3-(1-methylethylamino) propoxy]phenyl]ethanamide | C14H22N2O3 | 266,34 | 29122-68-7 |
Bezafibrate 2-{4-[2-(4-Chlorbenzamido)ethyl]phenoxyl}-2- | C19H20ClNO4 | 361,80 | 41859-67-0 |
Bisoprolol (RS)-1-[4-(2-Isopropoxyethoxymethyl)phenoxy]-3- | C18H31NO4 | 325,45 | 66722-44-9 |
Carbamazepine 5H-Dibenzo[b,f]azepine-5-carbamide | C15H12N2O | 236,27 | 298-46-4 |
Clarithromycin (2R,3R,4S,5R,8R,9S,10S,11R,12R,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3,4-dihydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl]oxy-12-methoxy-2,4,8,10,12,14-hexa- | C38H69NO13 | 747,95 | 81103-11-9 |
Clofibric acid 2-(4-Chlorophenoxy)-2-methylpropanoic acid | C10H11ClO3 | 214,70 | 882-09-7 |
Dehydrato-Erythromycin (anhydro-erythromycin) (2R,3R,4S,5S,8R,9S,10S,11R,12R)-11-{[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-5-ethyl-3-hydroxy-9-[(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy]-2,4,8,10,12,14-hexamethyl-6,15,16-trioxatricyclo[10.2.1.1{1,4}]hexadecane-7-one | C37H65NO12 | 715,91 | 23893-13-2 |
Diazepam (RS)-7-Chlor-1-methyl-5-phenyl-1,3-dihydro-2H-1,4- | C16H13ClN2O | 284,74 | 439-14-5 |
Diclofenac 2-[2-[(2,6-Dichlorphenyl)amino]phenyl]acetic acid | C14H11Cl2NO2 | 296,15 | 15307-86-5 |
10,11-Dihydro-10,11-dihydroxy carbamazepine (5S,6S)-5,6-Dihydroxy-5,6-dihydrobenzo[b][1]benzazepie-11-carboxamide | C15H14N2O3 | 270,29 | 58955-93-4 |
Erythromycin 6-(4-Dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)-oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione | C37H67NO13 | 733,93 | 114-07-8 |
4-Formylaminoantipyrine N-(2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)formamide | C12H13N3O2 | 231,25 | 1672-58-8 |
Gemfibrozil 5-(2,5-Chlorophenoxy)-2,2-methylpropanoic acid | C15H22O3 | 250,34 | 25812-30-0 |
Ibuprofen (RS)-2-[4-(2-Methylpropyl)phenyl]propanoic acid | C13H18O2 | 206,28 | 15687-27-1 |
Iomeprol (±)-N,N′-Bis-(2,3-dihydroxypropyl)-5-[(2-hydroxy-acetyl)methylamino]-2,4,6-triiodo isophthalamide | C17H22I3N3O8 | 777,09 | 78649-41-9 |
Iopamidol (S)-N,N′-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxypropanoyl)amino]-2,4,6-triiodobenzene-1,3-dicarbamide | C17H22I3N3O3 | 777,08 | 60166-93-0 |
Iopromide (±)-N,N′-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5- | C18H24I3N3O8 | 791,12 | 73334-07-3 |
Metoprolol (RS)-1-(Isopropylamino)-3-[4-(2-methoxyethyl) phenoxy]propan-2-ol | C15H25NO3 | 267,36 | 37350-58-6 |
Naproxen (S)-2-(6-Methoxy-2-naphthyl)propanoic acid | C14H14O3 | 230,26 | 22204-53-1 |
Oxazepam (RS)-7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4- | C15H11ClN2O2 | 286,71 | 604-75-1 |
Phenazone 1,5-Dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-on | C11H12N2O | 188,23 | 60-80-0 |
Primidone 5-Ethyl-5-phenylhexahydropyrimidin-4,6-dione | C12H14N2O2 | 218,25 | 125-33-7 |
Propyphenazone 1,5-Dimethyl-4-(1-methylethyl)-2-phenyl-1,2-dihydro-3H- | C14H18N2O | 230,31 | 479-92-5 |
Roxithromycin (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-10-(2,4,7-trioxa-1-azaoctan-1-ylidene)-1- | C41H76N2O15 | 837,05 | 80214-83-1 |
Sotalol (RS)-4′-(1-Hydroxy-2-isopropylaminoethyl) | C12H20N2O3S | 272,36 | 3930-20-9 |
Sulfamethoxazole 4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-sulfonamide | C10H11N3O3S | 253,28 | 723-46-6 |
Temazepam (RS)-7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one | C16H13ClN2O2 | 300,74 | 846-50-4 |
Trimethoprim 2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine | C14H18N4O3 | 290,32 | 738-70-5 |
a IUPAC: International Union of Pure and Applied Chemistry.
b CAS-RN: Chemical Abstracts System Registration Number.